Live lentogenic Newcastle disease virus bulk antigen destined for drinking-water administration is produced by inoculation of 9- to 11-day-old specific-pathogen-free embryonated chicken eggs, incubation for 48–72 h, and chilled allantoic fluid harvest. The harvested allantoic fluid typically contains infective Newcastle disease virus at titres between 10^9.0 and 10^10.0 EID₅₀/mL; the titre is adjusted by blending clarified harvests with a sterile stabiliser solution at a volume ratio of 1:1 before lyophilization. The stabiliser solution commonly contains sucrose at 5% w/v, hydrolysed gelatin at 1% w/v, potassium glutamate at 1% w/v, and monopotassium phosphate–dipotassium phosphate buffer at 0.02 M pH 7.2. Clarification is performed by low-speed continuous centrifugation at 4 °C followed by 0.45 µm membrane filtration; a 0.22 µm sterilising filter is not used because Newcastle disease virus is a pleomorphic enveloped virus with particle dimensions of approximately 150–300 nm. The filtered virus-stabiliser blend is filled into Type I glass vials and lyophilized on a stainless-steel shelf freeze dryer. The shelf is ramped to −40 °C at 0.5 °C/min, held for 4 h, primary dried at −20 °C and 80 µbar chamber pressure, and secondary dried at +25 °C and 50 µbar until residual moisture is not more than 2.0% w/w.Reconstitution for mass drinking-water application requires cold potable water with free chlorine below 0.1 ppm and pH between 5.5 and 7.5. Chlorine and oxidative sanitisers inactivate live Newcastle disease virus rapidly; free chlorine at 1 ppm can reduce infectivity by more than 1 log₁₀ within 60 min. Where raw water contains chlorine, the reconstitution water is pre-treated with sodium thiosulfate at 2.5 g per 1000 L or with skim milk powder at 2.5 g/L as a proteinaceous neutraliser. A single drinking-water batch is prepared by first dissolving the lyophilized cake in 2–5 L of pre-cooled water, then diluting through a calibrated proportioner at 1:100 or 1:200 injection ratio to deliver the target dose. The final water volume for 1,000 broiler doses is typically 10–20 L; layer pullets may require 15–25 L per 1,000 birds depending on barn temperature and flock drinking rate. The reconstituted vaccine must be consumed within 2 h when held at 15–20 °C; holding at 25–30 °C causes dose-critical titre loss.

In-use parameter	Limit or target
Free chlorine residual	<0.1 ppm
Reconstitution water pH	5.5–7.5
Sodium thiosulfate neutraliser	2.5 g/1000 L
Skim milk neutraliser	2.5 g/L
Proportioner injection ratio	1:100 to 1:200
Water temperature	15–20 °C
Consumption interval after reconstitution	≤2 h
Minimum release titre per bird dose	106.0 EID50

Finished product release for this presentation is governed by Ph. Eur. monograph 0450 for Newcastle disease vaccine (live), with sterility controlled according to Ph. Eur. 2.6.1 and mycoplasma absence according to Ph. Eur. 2.6.7. The terminal dosage form is a lyophilized cake in a glass vial containing 1,000, 2,500, or 5,000 bird doses. Lot-to-lot variance arises mainly from allantoic fluid titre variation; in-process blending to a target final titre reduces batch variance but does not remove the requirement for post-lyophilization potency testing.

Freeze-Dried Tablet and Cold-Water Granule Disintegration in Proportioning Systems

Freeze-dried tablet presentations are manufactured not by high-pressure compression of a dried cake but by aseptic dispensing of liquid virus-stabiliser slurry into pre-formed polyvinyl chloride or aluminium blister cavities, followed by freeze drying in-place. The resulting porous tablet contains the same virus-stabiliser matrix as a vial cake and can be dropped directly into a proportioner stock tank without breaking glass. Tablet mass is set to contain 100, 500, or 1,000 doses; uniformity of mass is tested according to Ph. Eur. 2.9.5 and disintegration according to Ph. Eur. 2.9.1 using water at 15 °C. A formulation with sucrose at 5% w/v, mannitol at 2% w/v, and dextran 40 at 1% w/v produces a tablet that disintegrates within 3 min without mechanical stirring. Cold-water granules are produced by fluid-bed drying at inlet air temperature 25–30 °C and dew point −30 °C, with product temperature maintained below 20 °C to avoid titre loss. The granule matrix uses maltodextrin at 5% w/v and trehalose at 10% w/v as amorphous protectants, giving a final granule particle size of 200–800 µm.Use ratio in the field differs from vial cake because the tablet or granule is first dissolved in a small pre-cooled stock volume of 2 L per 1,000 doses, then injected into drinking-water mains through a proportioner set at 1:100 or 1:200. The terminal product must never be exposed to water above 25 °C, chlorinated water above 0.1 ppm free chlorine, or pH outside 5.5–7.5 during reconstitution. A tablet formulation is not suitable for dry feed administration because the dried virus cannot survive intestinal transit unless a protective cold-chain reconstitution step is included. Compliance with Ph. Eur. 0450 and Ph. Eur. 0478 is required when the tablet is a finished pharmaceutical form; release testing includes mycoplasma absence per Ph. Eur. 2.6.7 and sterility of intermediates per Ph. Eur. 2.6.1. The most common process conflict is residual moisture in tablets; blister package water vapour transmission must be below 0.5 g/m²/day at 25 °C and 60% relative humidity to maintain titre stability for 24 months at 2–8 °C.

What Limits Oculonasal Titre Retention After Reconstitution?

Individual bird priming by oculonasal instillation requires the lyophilized powder or freeze-dried tablet to be reconstituted in a preservative-free diluent at a fixed volume of 0.03 mL per eye or nare. A 1,000-dose vial is therefore reconstituted in exactly 30 mL of diluent, producing a drop size that must be calibrated under field conditions because bird-to-bird variation in head movement changes the delivered dose. The diluent is phosphate-buffered saline at pH 7.2 with sucrose at 2% w/v; no chlorinated water, no tap water, and no multidose diluent containing thimerosal are used. Aseptic technique is required after reconstitution because the diluted vaccine supports bacterial growth and the live virus is not preserved. Titre retention after reconstitution is limited by aqueous thermal decay; at 20–25 °C, a batch-specific loss of 0.2–0.5 log₁₀/h is typically expected, while at 30 °C the loss can exceed 1 log₁₀ over 2 h. Published data for a specific stabilizer matrix are product-specific; formulators must generate in-use stability under Ph. Eur. 0450 because thermal decay rates change with sucrose crystallinity and residual moisture.Process control for commercial oculonasal administration uses a calibrated automatic dropper or single-use pipette with a delivery tolerance of ±10%. Drop size is verified with a graduated capillary tube at 20 °C. The terminal product is a clear or slightly opalescent solution after reconstitution; visible particles indicate incorrect diluent temperature or stabilizer precipitation and the preparation must be discarded. The route is used for priming before drinking-water booster vaccination in layers, breeders, and some broiler programs where early mucosal immunity is required. Compliance requires identity and potency per Ph. Eur. 0450 and release titre not less than the marketing authorisation limit for the oculonasal route; typical target release is 10^6.0–10^6.5 EID₅₀ per 0.03 mL dose.Hatchery spray administration delivers live Newcastle disease virus to day-old chicks as a coarse droplet with a target volume of 0.15–0.30 mL per bird and a droplet size distribution of 80–150 µm. The virus-stabiliser powder is reconstituted in distilled or deionized water, not saline, because saline accelerates droplet crystallisation and causes virus inactivation on the feathers and nasal epithelium. A cabinet sprayer is configured with 2–4 calibrated nozzles at 1.5–2.0 bar air pressure, delivering 200 mL per 1,000 chicks through a closed box to reduce drift. Relative humidity is maintained at 60–70% and ambient temperature at 20–25 °C; droplet residence time between nozzle and chick is 5–15 s. When relative humidity falls below 40%, the aqueous phase evaporates before inhalation and the titre available at the nasal mucosa drops below the dose target.The reconstitution ratio for spray application is one 1,000-dose vial diluted to 200–300 mL with cool distilled water; spraying 100 mL per 1,000 birds should be avoided because smaller droplet volumes increase evaporative loss. Stabilizer additives are limited to hydrolysed gelatin at 0.5% w/v or skim milk powder at 2% w/v; sucrose alone is insufficient under spray drying because it crystallises and forms sharp edges that can damage the virus envelope. The terminal product is a fine mist suspension in the hatchery cabinet; it is not a stable aerosol, and the vaccine must be used within 2 h after reconstitution. Compliance for spray administration is derived from the same Ph. Eur. 0450 potency requirement as oculonasal use, but the spray route requires additional in-use droplet titre recovery studies using a cascade impactor or all-glass impinger to verify that the cabinet delivers at least the minimum titre per chick. Field failure modes include clogged nozzles, pressure drop in central compressed-air lines, and accidental use of hard water containing dissolved ions.

When Injection Is Specified on a Finished Veterinary Product Dossier

Live Newcastle disease virus is not a standard injectable antigen. Veterinary pharmacopoeial monographs for injectable Newcastle disease vaccines describe inactivated antigen, not live virus. If a finished product specification lists injection as a route, the live API cannot be formulated into the same oil-emulsion adjuvanted systems used for inactivated Newcastle disease vaccines because the live virus envelope is disrupted by oil-water interfacial tension and surfactant components. Bulk live Newcastle disease virus particles are pleomorphic and range from 150–300 nm; terminal sterile filtration through a 0.22 µm membrane is not feasible without an unacceptable loss of infectivity. An aseptic liquid presentation may be prepared by buffer exchange of clarified allantoic fluid into phosphate-buffered saline pH 7.2 with sucrose at 5% w/v, followed by aseptic filling; the resulting product must be stored at 2–8 °C and used within 24 h unless frozen at −80 °C with a cryoprotectant. No standard pharmacopoeial monograph defines a release titre for live injectable Newcastle disease vaccine; published data for this specific configuration is limited.Process compliance for the non-standard injectable form would require sterility per Ph. Eur. 2.6.1, mycoplasma absence per Ph. Eur. 2.6.7, extraneous agent testing per USDA 9 CFR 113.26, and a product-specific parenteral safety study. The bulk harvest is clarified at 4 °C by centrifugation at 2,000 × g for 20 min, then filtered through a 0.45 µm membrane before buffer exchange by diafiltration with a 300 kDa cut-off membrane. The virus titre after diafiltration is adjusted to 10^6.0 EID₅₀/0.5 mL only if a parenteral use is explicitly approved by the competent authority. The terminal product is not a sustained-release or oil-adjuvanted injection; inactivated Newcastle disease vaccine should be selected for parenteral programs.Oral capsule development for live Newcastle disease virus is constrained by moisture sensitivity, gastric inactivation, and the absence of a pharmacopoeial capsule-specific release standard for live virus vaccines. A capsule presentation would require a lyophilized virus powder blend with a water activity below 0.2 and filling under 30% relative humidity at 20 °C. Hard gelatin capsules are less suitable than hydroxypropyl methylcellulose capsules because gelatin moisture content in equilibrium with 30% RH remains near 8% and can accelerate titre loss; HPMC capsules maintain lower equilibrium moisture. The powder blend may use lactose monohydrate at 70% w/w, microcrystalline cellulose at 20% w/w, and magnesium stearate at 0.25% w/w, but published data for this specific configuration is limited. The capsule shell is sealed and enteric coated with Eudragit L 30 D-55 at 7–10% weight gain in a pan coater with product temperature 18–22 °C and inlet air dew point below −20 °C.The terminal product would be an enteric capsule intended to release live virus in the jejunum; however, no commercial live Newcastle disease vaccine capsule exists in most regulated markets and no Ph. Eur. monograph for Newcastle disease vaccine defines capsule disintegration or titre release. In vitro titre recovery is tested in simulated intestinal fluid pH 6.8 with 1% w/v skim milk as a protective protein; dissolution apparatus using paddle speed 50 rpm at 37 °C may be used for physical disintegration, but infectivity recovery must be measured by titration in embryonated eggs or cell culture. The most critical process conflict is the enteric coating aqueous dispersion; overspraying beyond 10% weight gain increases residual water and reduces virus titre. Capsule presentation is therefore a research or autogenous platform, not a standard field product.

Co-Formulation with Infectious Bronchitis Virus Shifts Freeze-Drying Collapse Boundaries

Combination live poultry vaccines containing Newcastle disease virus and infectious bronchitis virus are prepared by blending separately clarified allantoic fluid harvests before stabiliser addition. The Newcastle disease virus bulk is adjusted to a final release titre of 10^6.0 EID₅₀ per dose, while the infectious bronchitis virus component is adjusted to a titre defined by the marketing authorisation, commonly not less than 10^3.5 EID₅₀ per dose. The blend ratio is calculated from pre-blend potency data; final volume is made up with a stabiliser containing sucrose at 10% w/v, glycine at 1% w/v, and hydrolysed gelatin at 1% w/v. The stabiliser level is higher than single-antigen Newcastle disease vaccine because the infectious bronchitis virus component is more thermolabile during freeze drying and the combined plug must retain both titre values after 24 months at 2–8 °C.Lyophilization of the co-formulated plug requires a cycle re-validation because the collapse temperature of the combined matrix may differ from that of the single Newcastle disease virus cake. Published collapse data for the specific co-formulation is limited; each manufacturer must perform freeze-drying microscopy and product temperature mapping with thermocouples or manometric temperature measurement. The drying shelf is typically ramped to −40 °C, primary dried at −10 °C and 80 µbar, and secondary dried at +20 °C and 50 µbar; residual moisture is controlled to not more than 2.0% w/w. The terminal product is a 1,000-dose freeze-dried plug for drinking water or oculonasal reconstitution; spray administration of combination vaccine requires field validation because droplet size differences between the two viruses do not alter the live virus titre but may affect distribution. Compliance is against Ph. Eur. 0450 and Ph. Eur. 0442 for the infectious bronchitis component, with extraneous agent testing per Ph. Eur. 2.6.7 and USDA 9 CFR 113.26. Incompatibility arises if the live co-formulated vaccine is mixed with inactivated oil-emulsion Newcastle disease vaccine in the same syringe or administration line.Feed premix and pelleted feed formats expose live Newcastle disease virus to thermal and mechanical stress that exceeds the survival envelope of lyophilized antigen. Steam conditioning in poultry feed mills operates at 70–80 °C for 30–60 s under 2–3 bar gauge pressure, and post-conditioning pellet die temperatures can exceed 75 °C. Live Newcastle disease virus is thermolabile; heating at 56 °C for 30 min is sufficient to inactivate most infectivity, and the higher temperatures and short residence times in feed pelleting reduce live virus titre below the threshold needed for mucosal vaccination. A feed premix based on direct spray-drying or coating of live virus onto feed particles is therefore not a recognised commercial Newcastle disease vaccine format. Granule or powder presentations labelled as premix are acceptable only when the dry blend is dissolved in drinking water immediately before use; the dry carrier is not intended for oral intake as a feed additive.Cold-water soluble premix granules use lactose monohydrate at 80% w/w, skim milk powder at 10% w/w, sodium thiosulfate at 2% w/w, and citric acid at 0.5% w/w as a carrier, with lyophilized virus blended at low shear in a room maintained at 2–8 °C and 30% relative humidity. The blend is filled into aluminium foil sachets and sealed under nitrogen; residual oxygen below 1% and residual moisture below 2.0% w/w are batch-release criteria. For feed mill integration, the sachet is emptied into the drinking-water header tank, not into the mixer or pellet mill. The terminal product is a water-dispersible premix for mass application, not a pelleted feed vaccine. Compliance for the dry premix follows Ph. Eur. 0450 for the live antigen and requires in-use stability data under the same monograph.

Feed-processing stress parameter	Limit or target
Steam conditioning temperature	70–80 °C
Retention time	30–60 s
Pellet die temperature	>75 °C
Live virus thermal stability reference	56 °C for 30 min
Dry blend storage	2–8 °C
Sachet residual oxygen	<1%
Sachet residual moisture	<2.0% w/w